161 related articles for article (PubMed ID: 2505017)
1. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.
Grant MB; Fitzgerald C; Guay C; Lottenberg R
Metabolism; 1989 Sep; 38(9):901-7. PubMed ID: 2505017
[TBL] [Abstract][Full Text] [Related]
2. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
[TBL] [Abstract][Full Text] [Related]
3. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
5. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease.
Pecori Giraldi F; Ambrogio AG; Fatti LM; Rubini V; Cozzi G; Scacchi M; Federici AB; Cavagnini F
Br J Clin Pharmacol; 2011 Jan; 71(1):132-6. PubMed ID: 21143510
[TBL] [Abstract][Full Text] [Related]
7. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.
Vicente V; Estellés A; Laso J; Moraleda JM; Rivera J; Aznar J
Thromb Res; 1993 Apr; 70(2):117-22. PubMed ID: 8322282
[TBL] [Abstract][Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
9. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
10. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
Wieczorek I; Ludlam CA; MacGregor IR
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
[TBL] [Abstract][Full Text] [Related]
11. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
12. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Auwerx J; Bouillon R; Collen D; Geboers J
Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
[TBL] [Abstract][Full Text] [Related]
13. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
[TBL] [Abstract][Full Text] [Related]
14. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
15. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
Patrassi GM; Sartori MT; Casonato A; Viero ML; Pontara E; Saggiorato G; Girolami A
Thromb Res; 1992 Jun; 66(5):517-26. PubMed ID: 1523608
[TBL] [Abstract][Full Text] [Related]
17. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients.
Gram J; Jespersen J
Am J Med; 1991 Jun; 90(6A):62S-66S. PubMed ID: 1908183
[TBL] [Abstract][Full Text] [Related]
18. The rabbit as a model for studies of fibrinolysis.
Hassett MA; Krishnamurti C; Barr CF; Alving BM
Thromb Res; 1986 Aug; 43(3):313-23. PubMed ID: 3488605
[TBL] [Abstract][Full Text] [Related]
19. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
